Does the Mediterranean G6PD S188F Polymorphism Confer Vascular Protection?
Yao Li,Patrick J Pagano
DOI: https://doi.org/10.1161/hypertensionaha.120.14897
IF: 9.8968
2020-01-01
Hypertension
Abstract:HomeHypertensionVol. 76, No. 2Does the Mediterranean G6PD S188F Polymorphism Confer Vascular Protection? Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBDoes the Mediterranean G6PD S188F Polymorphism Confer Vascular Protection?A Novel Rat Model Offering CRISPR Insight Into High Fat–Induced Vascular Dysfunction and Hypertension Yao Li and Patrick J. Pagano Yao LiYao Li From the Heart, Lung, Blood and Vascular Medicine Institute and Department of Pharmacology and Chemical Biology, University of Pittsburgh, PA. Search for more papers by this author and Patrick J. PaganoPatrick J. Pagano Correspondence to Patrick J. Pagano, Department of Pharmacology and Chemical Biology, University of Pittsburgh, 200 Lothrop St, BST-E1247, Pittsburgh, PA 15261. Email E-mail Address: [email protected] From the Heart, Lung, Blood and Vascular Medicine Institute and Department of Pharmacology and Chemical Biology, University of Pittsburgh, PA. Search for more papers by this author Originally published8 Jul 2020https://doi.org/10.1161/HYPERTENSIONAHA.120.14897Hypertension. 2020;76:314–315This article is a commentary on the followingCRISPR-Mediated Single Nucleotide Polymorphism Modeling in Rats Reveals Insight Into Reduced Cardiovascular Risk Associated With Mediterranean G6PD VariantSee related article, pp 523–532Glucose-6-phosphate dehydrogenase (G6PD), the first enzyme and rate-limiting step in the pentose phosphate pathway, oxidizes glucose-6-phosphate to 6-phosphogluconolactone, while also serving as a major cell generator of NADPH. As such, G6PD predictably subserves both anti- and pro-oxidant effects in cells.1,2 Via the generation of NADPH, G6PD replenishes reduced glutathione (GSH) from oxidized glutathione (GSSG). It stands to reason then that a polymorphism in G6PD leading to G6PD insufficiency would be expected to increase the GSSG-to-GSH ratio and decrease GSH reductase activity and H2O2 levels.3 eNOS (endothelial NO synthase) and other NOS (NO synthase) isozymes rely on NADPH to convert arginine to citrulline while liberating NO.1 Further, NADPH is the substrate for the Nox (NADPH oxidase) family of enzymes, major sources of reactive oxygen species/reactive nitrogen species in the cardiovascular system4 and myriad other organ systems. Modulation in NADPH levels is expected to cause aberrations in liver metabolic cytochrome P450 and other oxidoreductases that require NADPH as a cofactor. All told, the contribution of G6PD and NADPH is likely to be much more complex than its effects on GSH peroxidase, NOS, and oxidoreductases since an increased oxidation state of a cell or cellular compartment is known to have profound effects on proteins ranging from tyrosine kinases to calcium channels.In this issue, Kitagawa et al5 shed light on our understanding of the impact of G6PD deficiency (one of the most common enzyme deficiencies worldwide) on vascular function and blood pressure. As the authors reveal, the most common complications from G6PD deficiency are neonatal jaundice and hemolytic anemia. However, relevant to the current spotlighted study, the deficiency has been implicated in a higher incidence of hypertension in some cases although the data are not conclusive in that regard.3,6 On the contrary, studies have suggested that the Mediterranean polymorphism is vasoprotective.7–9 Employing CRISPR-Cas9 gene editing, the authors generate a novel rat model replicating a specific human Mediterranean single-nucleotide polymorphism (S188F) that is epidemiologically associated with a lower incidence of vascular disease in humans. With this model, the authors set out to interrogate a potential mechanism afforded by this polymorphism as to whether or not it can be vasculoprotective. Compared with WT (wild type) rats, livers from G6PD mutants display lower G6PD activity by 80%, increased GSSG-to-GSH ratio, and decreased nucleotide levels, all of which rather faithfully recapitulate the human phenotype.10To date, in vitro and in vivo manipulation of G6PD gene expression has yielded mixed results for vascular reactivity. Indeed, G6PD-deficient cells and animals can be more susceptible to oxidative damage and decreased NO levels than WT cells/mice; and animals overexpressing G6PD may be protected against oxidation and generate greater NO.1,3 On the other hand, studies have suggested that hyperlipidemia and hyperglycemia potentiate G6PD activity and NADPH levels leading to augmented superoxide anion production from Nox2 and rat myocardial and vascular dysfunction.11Intriguingly in the current study, the authors’ findings are supportive of a potential reduced propensity for cardiovascular disease in the Mediterranean single-nucleotide polymorphism cohort consistent with clinical data in humans.7–9 Indeed, the high-fat diet representative of metabolic syndrome and applied in the current study is expected to induce vascular abnormalities including vascular dysfunction, inflammation, and vessel stiffening, which all combine to cause greater vasoconstriction and increased blood pressure. However, a lesser increase in systolic and diastolic blood pressure and arterial stiffness was observed in G6PD mutant rats versus WT rats, suggesting that these G6PD-deficient rats are less prone to vascular pathologies elicited by high fat. Moreover, the authors show that the same changes (observed in response to NOS inhibition) in WT rats are markedly attenuated or abrogated in G6PD-deficient rats. As G6PD-derived NADPH is required for NOS-mediated NO production,1 it stands to reason that with lower G6PD activity, mutant rats would have decreased NO synthase activity, and thus application of the NO synthase inhibitor L-NAME (N[ω]-Nitro-L-arginine methyl ester hydrochloride) would yield a lesser response in the G6PD-deficient rats. While the authors conclude that these results are surprising in that they suggest WT arteries are on the whole less functional or healthy than those from mutant rats, the answer may not be that simple. Indeed, at face value, these results might imply that G6PD knockdown, per se, is protective. However, as these rats were deficient since early gestation as global mutants, they may well have developed compensatory protective mechanisms. The findings that WT and G6PD mutant rats have the same baseline blood pressure, arterial stiffness, and acetylcholine-induced relaxation are consistent with that notion.That notwithstanding, with an eye toward deciphering potential protective mechanisms conferred by the G6PD mutation with respect to high fat, the authors proceed to elegantly deconstruct how the vasculature may be protected against the metabolic insult. Toward that end, they present very interesting findings implying that the activity (and not expression) of voltage-gated calcium channels is the culprit—illustrating a higher sensitivity to a selective activator of vascular L-type Ca2+ channels (Bay K8644) in WT compared with G6PD-compromised rats. In more detail, Bay K8644 caused a robust increase in both systolic and diastolic blood pressure in WT rats that was absent in G6PD-deficient rats. Through a series of well-integrated approaches, the authors demonstrate a strikingly lower membrane potential and calcium influx into arterial smooth muscle cells and, in turn, virtual obliteration of KCl-induced vascular constriction and blood pressure rises in the mutants. Hyperpolarization of vascular smooth muscle is proffered as protective in G6PD-deficient rats, which may be attributed to, as the authors proposed, a variety of changes in activities of potassium channels including BKCa and inward rectifier K+ channels, backed up by augmented Kcnmb1 (β-subunit of BKCa) and a suppressed polyamine pathway, respectively.The authors have made several intriguing observations in the G6PD-deficient rats. Still, the current work opens the door to a series of important questions. First and foremost, what redox intermediary, per se, causes the diminished activity of calcium channels and thus vascular reactivity or what mechanistic link connects the measured increase in GSSG and the abovementioned modulators of membrane hyperpolarization? That is, whether changes in peroxide levels cause alterations in calcium channel activity and whether such elevations in peroxides or GSSG bring forth measurable modification in key cysteines on proteins expected to enhance K+ channel activities warrant deeper analysis. Further, as the G6PD mutation is global and extant from the embryonic stage, broad modulation of key proteins and enzyme systems might be brought to bear that are germane to vascular function and hypertension and be corrected with time (to a lesser or greater) degree in the mutant rat versus the human cohort. More to the point, how G6PD deficiency affects superoxide dismutase, catalase, and other enzyme systems in the mutant rats versus human G6PD-deficient cohort might provide greater insight in this regard.Despite these unanswered questions, the current study by Kitagawa et al is conceptually novel, technologically sophisticated, and provides a significant advancement in our understanding of how G6PD and NADPH levels might affect vascular tone and blood pressure under aberrant metabolic conditions. This rat model is expected to provide numerous new mechanistic insights into the manifold ways G6PD activity influences cell signaling in the vasculature and beyond. With G6PD at the nexus of a broad range of essential non–redox-sensitive pathways and redox-sensitive pathways, this new model provides a platform on which wide-ranging inquiries may be made.Sources of FundingThis work is supported by the National Institutes of Health Grants R01HL142248, R01HL079207, R01HL112914, T32GM008424, and AHA 18TPA34170069. This work was also supported by the Institute for Transfusion Medicine, the Hemophilia Center of Western Pennsylvania and the Heart, Lung, Blood and Vascular Medicine Institute of the University of Pittsburgh School of Medicine.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the American Heart Association.Correspondence to Patrick J. Pagano, Department of Pharmacology and Chemical Biology, University of Pittsburgh, 200 Lothrop St, BST-E1247, Pittsburgh, PA 15261. Email [email protected]eduReferences1. Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival.IUBMB Life. 2012; 64:362–369. doi: 10.1002/iub.1017CrossrefMedlineGoogle Scholar2. Stincone A, Prigione A, Cramer T, Wamelink MM, Campbell K, Cheung E, Olin-Sandoval V, Grüning NM, Krüger A, Tauqeer Alam M, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway.Biol Rev Camb Philos Soc. 2015; 90:927–963. doi: 10.1111/brv.12140CrossrefMedlineGoogle Scholar3. Hecker PA, Leopold JA, Gupte SA, Recchia FA, Stanley WC. Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease.Am J Physiol Heart Circ Physiol. 2013; 304:H491–H500. doi: 10.1152/ajpheart.00721.2012CrossrefMedlineGoogle Scholar4. Li Y, Pagano PJ. Microvascular NADPH oxidase in health and disease.Free Radic Biol Med. 2017; 109:33–47. doi: 10.1016/j.freeradbiomed.2017.02.049CrossrefMedlineGoogle Scholar5. Kitagawa A, Kizub I, Jacob C, Michael K, D’Alessandro A, Reisz JA, Grzybowski M, Geurts AM, Rocic P, Gupte R, et al. CRISPR-mediated single nucleotide polymorphism modeling in rats reveals insight into reduced cardiovascular risk associated with mediterranean G6PD variant.Hypertension. 2020; 766:523–532. doi: 10.1161/HYPERTENSIONAHA.120.14772LinkGoogle Scholar6. Parsanathan R, Jain SK. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is linked with cardiovascular disease.Hypertens Res. 2020; 43:582–584. doi:10.1038/s41440-020-0402-8CrossrefMedlineGoogle Scholar7. Cocco P, Todde P, Fornera S, Manca MB, Manca P, Sias AR. Mortality in a cohort of men expressing the glucose-6-phosphate dehydrogenase deficiency.Blood. 1998; 91:706–709.CrossrefMedlineGoogle Scholar8. Pinna A, Contini EL, Carru C, Solinas G. Glucose-6-phosphate dehydrogenase deficiency and diabetes mellitus with severe retinal complications in a Sardinian population, Italy.Int J Med Sci. 2013; 10:1907–1913. doi: 10.7150/ijms.6776CrossrefMedlineGoogle Scholar9. Meloni L, Manca MR, Loddo I, Cioglia G, Cocco P, Schwartz A, Muntoni S, Muntoni S. Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease.J Inherit Metab Dis. 2008; 31:412–417. doi: 10.1007/s10545-008-0704-5CrossrefMedlineGoogle Scholar10. Francis RO, Jhang JS, Pham HP, Hod EA, Zimring JC, Spitalnik SL. Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks.Vox Sang. 2013; 105:271–282. doi: 10.1111/vox.12068CrossrefMedlineGoogle Scholar11. Serpillon S, Floyd BC, Gupte RS, George S, Kozicky M, Neito V, Recchia F, Stanley W, Wolin MS, Gupte SA. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH.Am J Physiol Heart Circ Physiol. 2009; 297:H153–H162. doi: 10.1152/ajpheart.01142.2008CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesCRISPR-Mediated Single Nucleotide Polymorphism Modeling in Rats Reveals Insight Into Reduced Cardiovascular Risk Associated With Mediterranean G6PD VariantAtsushi Kitagawa, et al. Hypertension. 2020;76:523-532 August 2020Vol 76, Issue 2 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.120.14897PMID: 32639882 Originally publishedJuly 8, 2020 PDF download Advertisement SubjectsCell Signaling/Signal TransductionEndothelium/Vascular Type/Nitric OxideIon Channels/Membrane TransportOxidant StressVascular Biology